Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France’s Snitem Demands Shock Cardiac Devices Reimbursement Decision Be Reversed

Executive Summary

French medtech trade association, Snitem, and local cardiologists are stunned by the removal from the reimbursement list of two state-of-the art cardiology devices and are demanding their reinstatement.

You may also be interested in...



EU Regulatory Round-Up, March 2023: EU Deadlines Under MDR Amending Regulation Published And Clarified

This month’s round-up summarises the biggest EU medtech regulatory news in a year as legacy device transition periods are extended. A highly applauded commission summary of the new timelines under the EU’s MDR amending regulation provides key snapshot of the essential points.

Why Adding A Legacy Device To Eudamed Now, Before It is Mandatory, Is A Shrewd Move

The EU MDR amending regulation does not impact Eudamed directly, but it may make medtech manufacturers reconsider when to register legacy devices in Eudamed. Richard Houlihan of EirMed explains.

BSI Notified Body Highlights Crucial Elements Related To EU’s MDR Amending Regulation

BSI Group has issued a useful Q&A document on how it sees the new EU MDR amending Regulation, which extends the transition deadlines for legacy medical devices, impacting manufacturers and their relationship with notified bodies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel